Astal Laboratories Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 157295,
    "name": "Astal Lab",
    "stock_name": "Astal Lab",
    "full_name": "Astal Laboratories Ltd",
    "name_url": "stocks-analysis/astal-lab",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "79.30",
    "chg": -1.18,
    "chgp": "-1.47%",
    "dir": -1,
    "prev_price": "80.48",
    "mcapval": "346.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 512600,
    "symbol": "",
    "ind_name": "Trading & Distributors",
    "ind_code": 49,
    "indexname": "",
    "isin": "INE307N01014",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "4.51 k",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/astal-lab-157295-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Astal Lab overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-astal-lab-overvalued-or-undervalued-3745256",
        "imagepath": "",
        "date": "2025-12-04 08:18:34",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Strong Valuation Metrics Highlight Undervaluation</strong></p>\n<p>Astal Lab’s price-to-earnings (PE) ratio stands at a modest 9.14, significantly lower than many of its peers in the trading and distribution space, where valuations often exceed 20 or even 100 times earnings. This low PE ratio suggests the market is pricing the stock conservatively relative to its earnings potential. Complementing this, the price-to-book value ratio of 2.07 indicates the stock is trading at just over twice its net asset value, a reasonable level for a company with strong returns on equity.</p>\n<p>The enterprise value to EBITDA ratio of 6.76 and EV to EBIT of 6.96 further reinforce the stock’s undervaluation. These multiples are well below those of several competitors, some of which trade at multiples exceeding..."
      },
      {
        "title": "Why is Astal Lab falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-astal-lab-fallingrising-3744854",
        "imagepath": "",
        "date": "2025-12-04 00:29:08",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Performance and Market Comparison</strong></p>\n<p>Astal Laboratories has experienced a challenging period over the past month, with its stock price falling by 13.93%, contrasting sharply with the Sensex's gain of 1.34% during the same timeframe. This divergence highlights the stock's relative weakness amid a generally positive market environment. Year-to-date, the stock has managed a modest gain of 3.70%, yet this lags behind the Sensex's 8.92% advance. Over the last year, the stock has declined by 8.00%, while the benchmark index has risen by 5.27%, underscoring a persistent underperformance trend.</p>\n<p>On the day in question, Astal Laboratories underperformed its sector by 1.58%, signalling sector peers fared better. The stock has now declined for three consecutive days, acc..."
      },
      {
        "title": "How has been the historical performance of Astal Lab?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-astal-lab-3744702",
        "imagepath": "",
        "date": "2025-12-03 22:45:42",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue Growth and Operating Performance</strong></p>\n<p>Astal Lab's net sales have surged impressively from a modest ₹3.43 crores in the fiscal year ending March 2023 to ₹64.23 crores by March 2025. This exponential increase reflects the company's successful market penetration and scaling of operations. Total operating income mirrored this trend, rising from ₹3.43 crores to ₹64.23 crores over the same period, with no other operating income contributing to the top line.</p>\n<p>Raw material costs have understandably escalated in line with revenue growth, reaching ₹61.81 crores in March 2025 from zero reported in earlier years, indicating a shift from purchasing finished goods to in-house production. The company also reported a significant negative change in stocks, suggesting inventory build-..."
      },
      {
        "title": "Astal Laboratories Faces Cash Flow Challenges Despite Record Sales and Profitability",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/astal-laboratories-financial-trend-shifts-from-very-positive-to-positive-amid-cash-flow-challenges-3712011",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AstalLaboratori_fintrenddot_3712011.png",
        "date": "2025-11-18 14:00:10",
        "description": "Astal Laboratories reported record net sales of Rs 37.52 crore for the quarter ending September 2025, with a profit after tax of Rs 7.41 crore for the nine-month period. However, the company faces challenges with negative operating cash flow of Rs -12.52 crore, raising concerns about liquidity and operational efficiency."
      },
      {
        "title": "Astal Laboratories Q2 FY26: Explosive Growth Meets Margin Compression Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/astal-laboratories-q2-fy26-explosive-growth-meets-margin-compression-concerns-3718518",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AstalLaboratori_quaterlyResult_3718518.png",
        "date": "2025-11-18 12:33:48",
        "description": "Astal Laboratories Ltd., a micro-cap trading and distribution company with a market capitalisation of ₹96.00 crores, has delivered a quarter of remarkable top-line expansion tempered by margin compression concerns. In Q2 FY26, the company posted net profit of ₹2.58 crores, marking a 23.44% sequential increase from Q1 FY26's ₹2.09 crores and a robust 29.00% year-on-year growth from ₹2.00 crores in Q2 FY25. However, the stock has retreated 7.03% over the past week, trading at ₹88.80 as investors digest the margin dynamics beneath the headline numbers."
      },
      {
        "title": "Astal Laboratories Experiences Quality Grade Change Amidst Competitive Industry Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/astal-laboratories-downgraded-to-below-average-quality-grade-amid-strong-sales-growth-3709564",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AstalLaboratori_qualitydot_3709564.png",
        "date": "2025-11-18 08:00:11",
        "description": "Astal Laboratories, a microcap in the Trading & Distributors sector, has shown significant sales growth of 152.08% and EBIT growth of 72.67% over five years. Its financial metrics indicate manageable debt levels, but its return on capital employed and return on equity are relatively low, suggesting potential challenges ahead."
      },
      {
        "title": "How has been the historical performance of Astal Lab?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-astal-lab-3708553",
        "imagepath": "",
        "date": "2025-11-17 22:54:54",
        "description": "Answer:\nThe historical performance of Astal Lab shows significant growth in net sales and profitability over the years, particularly from March 2023 to March 2025.\n\nBreakdown:\nAstal Lab's net sales have increased dramatically from 3.43 crore in March 2023 to 64.23 crore in March 2025, reflecting a strong upward trend. The total operating income followed a similar trajectory, rising from 3.43 crore in March 2023 to 64.23 crore in March 2025. The company's total expenditure also rose, but at a slower pace, from 3.56 crore in March 2023 to 51.46 crore in March 2025, leading to an operating profit (PBDIT) of 12.90 crore in March 2025, up from just 0.05 crore in March 2023. Profit before tax reached 11.98 crore in March 2025, compared to only 0.03 crore in March 2023, while profit after tax surged to 8.93 crore from a mere 0.02 crore in March 2023. The earnings per share (EPS) also saw a substantial increase, fr..."
      },
      {
        "title": "How has been the historical performance of Astal Lab?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-astal-lab-3702919",
        "imagepath": "",
        "date": "2025-11-14 23:38:22",
        "description": "Answer:\nThe historical performance of Astal Lab shows significant growth in net sales and profitability over the years, particularly from March 2023 to March 2025.\n\nBreakdown:\nAstal Lab's net sales have surged from 3.43 Cr in March 2023 to 64.23 Cr in March 2025, indicating a robust growth trajectory. The total operating income followed a similar trend, increasing from 3.43 Cr in March 2023 to 64.23 Cr in March 2025. The company has also improved its operating profit, moving from a loss of 0.13 Cr in March 2023 to a profit of 12.90 Cr in March 2025, reflecting an operating profit margin of 19.88% in the latest fiscal year. Profit before tax rose from 0.03 Cr in March 2023 to 11.98 Cr in March 2025, while profit after tax increased from 0.02 Cr to 8.93 Cr in the same period, resulting in a PAT margin of 13.9%. On the balance sheet, total assets grew from 9.91 Cr in March 2023 to 63.34 Cr in March 2025, with ..."
      },
      {
        "title": "How has been the historical performance of Astal Lab?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-astal-lab-3694430",
        "imagepath": "",
        "date": "2025-11-12 23:38:59",
        "description": "Answer:\nThe historical performance of Astal Lab shows significant growth in net sales and profitability over the years, particularly from March 2023 to March 2025.\n\nBreakdown:\nAstal Lab's net sales surged from 3.43 crore in March 2023 to 64.23 crore in March 2025, reflecting a strong upward trend. Total operating income followed a similar trajectory, increasing from 3.43 crore in March 2023 to 64.23 crore in March 2025. The company's total expenditure also rose, but at a slower pace, from 3.56 crore in March 2023 to 51.46 crore in March 2025, leading to an operating profit (PBDIT) that improved from a loss of 0.13 crore in March 2023 to a profit of 12.90 crore in March 2025. Profit before tax also saw a remarkable increase, moving from 0.03 crore in March 2023 to 11.98 crore in March 2025, while profit after tax rose from 0.02 crore to 8.93 crore in the same period. The company's total assets grew significa..."
      }
    ],
    "total": 110,
    "sid": "157295",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/astal-laboratories-157295"
  },
  "announcements": [
    {
      "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
      "datetime": "24-Jan-2026",
      "details": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Aceso Research Labs LLP",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
      "datetime": "24-Jan-2026",
      "details": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Aceso Research Labs LLP",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011",
      "datetime": "23-Jan-2026",
      "details": "The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Sesha Sai Nikhil Chintalapati",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Is Astal Lab overvalued or undervalued?

2025-12-04 08:18:34

Strong Valuation Metrics Highlight Undervaluation Astal Lab’s price-to-earnings (PE) ratio stands at a modest 9.14, significantly lower than many of its peers in the trading and distribution space, where valuations often exceed 20 or even 100 times earnings. This low PE ratio suggests the market is pricing the stock conservatively relative to its earnings potential. Complementing this, the price-to-book value ratio of 2.07 indicates the stock is trading at just over twice its net asset value, a reasonable level for a company with strong returns on equity. The enterprise value to EBITDA ratio of 6.76 and EV to EBIT of 6.96 further reinforce the stock’s undervaluation. These multiples are well below those of several competitors, some of which trade at multiples exceeding...

Why is Astal Lab falling/rising?

2025-12-04 00:29:08

Recent Price Performance and Market Comparison Astal Laboratories has experienced a challenging period over the past month, with its stock price falling by 13.93%, contrasting sharply with the Sensex's gain of 1.34% during the same timeframe. This divergence highlights the stock's relative weakness amid a generally positive market environment. Year-to-date, the stock has managed a modest gain of 3.70%, yet this lags behind the Sensex's 8.92% advance. Over the last year, the stock has declined by 8.00%, while the benchmark index has risen by 5.27%, underscoring a persistent underperformance trend. On the day in question, Astal Laboratories underperformed its sector by 1.58%, signalling sector peers fared better. The stock has now declined for three consecutive days, acc...

How has been the historical performance of Astal Lab?

2025-12-03 22:45:42

Revenue Growth and Operating Performance Astal Lab's net sales have surged impressively from a modest ₹3.43 crores in the fiscal year ending March 2023 to ₹64.23 crores by March 2025. This exponential increase reflects the company's successful market penetration and scaling of operations. Total operating income mirrored this trend, rising from ₹3.43 crores to ₹64.23 crores over the same period, with no other operating income contributing to the top line. Raw material costs have understandably escalated in line with revenue growth, reaching ₹61.81 crores in March 2025 from zero reported in earlier years, indicating a shift from purchasing finished goods to in-house production. The company also reported a significant negative change in stocks, suggesting inventory build-...

Astal Laboratories Faces Cash Flow Challenges Despite Record Sales and Profitability

2025-11-18 14:00:10

Astal Laboratories reported record net sales of Rs 37.52 crore for the quarter ending September 2025, with a profit after tax of Rs 7.41 crore for the nine-month period. However, the company faces challenges with negative operating cash flow of Rs -12.52 crore, raising concerns about liquidity and operational efficiency.

Astal Laboratories Q2 FY26: Explosive Growth Meets Margin Compression Concerns

2025-11-18 12:33:48

Astal Laboratories Ltd., a micro-cap trading and distribution company with a market capitalisation of ₹96.00 crores, has delivered a quarter of remarkable top-line expansion tempered by margin compression concerns. In Q2 FY26, the company posted net profit of ₹2.58 crores, marking a 23.44% sequential increase from Q1 FY26's ₹2.09 crores and a robust 29.00% year-on-year growth from ₹2.00 crores in Q2 FY25. However, the stock has retreated 7.03% over the past week, trading at ₹88.80 as investors digest the margin dynamics beneath the headline numbers.

Astal Laboratories Experiences Quality Grade Change Amidst Competitive Industry Landscape

2025-11-18 08:00:11

Astal Laboratories, a microcap in the Trading & Distributors sector, has shown significant sales growth of 152.08% and EBIT growth of 72.67% over five years. Its financial metrics indicate manageable debt levels, but its return on capital employed and return on equity are relatively low, suggesting potential challenges ahead.

How has been the historical performance of Astal Lab?

2025-11-17 22:54:54

Answer: The historical performance of Astal Lab shows significant growth in net sales and profitability over the years, particularly from March 2023 to March 2025. Breakdown: Astal Lab's net sales have increased dramatically from 3.43 crore in March 2023 to 64.23 crore in March 2025, reflecting a strong upward trend. The total operating income followed a similar trajectory, rising from 3.43 crore in March 2023 to 64.23 crore in March 2025. The company's total expenditure also rose, but at a slower pace, from 3.56 crore in March 2023 to 51.46 crore in March 2025, leading to an operating profit (PBDIT) of 12.90 crore in March 2025, up from just 0.05 crore in March 2023. Profit before tax reached 11.98 crore in March 2025, compared to only 0.03 crore in March 2023, while profit after tax surged to 8.93 crore from a mere 0.02 crore in March 2023. The earnings per share (EPS) also saw a substantial increase, fr...

How has been the historical performance of Astal Lab?

2025-11-14 23:38:22

Answer: The historical performance of Astal Lab shows significant growth in net sales and profitability over the years, particularly from March 2023 to March 2025. Breakdown: Astal Lab's net sales have surged from 3.43 Cr in March 2023 to 64.23 Cr in March 2025, indicating a robust growth trajectory. The total operating income followed a similar trend, increasing from 3.43 Cr in March 2023 to 64.23 Cr in March 2025. The company has also improved its operating profit, moving from a loss of 0.13 Cr in March 2023 to a profit of 12.90 Cr in March 2025, reflecting an operating profit margin of 19.88% in the latest fiscal year. Profit before tax rose from 0.03 Cr in March 2023 to 11.98 Cr in March 2025, while profit after tax increased from 0.02 Cr to 8.93 Cr in the same period, resulting in a PAT margin of 13.9%. On the balance sheet, total assets grew from 9.91 Cr in March 2023 to 63.34 Cr in March 2025, with ...

How has been the historical performance of Astal Lab?

2025-11-12 23:38:59

Answer: The historical performance of Astal Lab shows significant growth in net sales and profitability over the years, particularly from March 2023 to March 2025. Breakdown: Astal Lab's net sales surged from 3.43 crore in March 2023 to 64.23 crore in March 2025, reflecting a strong upward trend. Total operating income followed a similar trajectory, increasing from 3.43 crore in March 2023 to 64.23 crore in March 2025. The company's total expenditure also rose, but at a slower pace, from 3.56 crore in March 2023 to 51.46 crore in March 2025, leading to an operating profit (PBDIT) that improved from a loss of 0.13 crore in March 2023 to a profit of 12.90 crore in March 2025. Profit before tax also saw a remarkable increase, moving from 0.03 crore in March 2023 to 11.98 crore in March 2025, while profit after tax rose from 0.02 crore to 8.93 crore in the same period. The company's total assets grew significa...

View All News